{"id":"high-dose-trivalent-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site soreness"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-15","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains three inactivated influenza virus strains (typically two A subtypes and one B type) at higher antigen concentrations than standard-dose formulations. This increased antigenic load triggers more robust activation of B cells and T cells, leading to higher titers of neutralizing antibodies and improved cell-mediated immunity, particularly beneficial in older adults with waning immune responses.","oneSentence":"High-dose trivalent influenza vaccine stimulates a stronger immune response by delivering increased antigen quantities to enhance antibody production and cellular immunity against three influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:13.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza A and B in adults aged 65 years and older"},{"name":"Prevention of influenza in immunocompromised populations"}]},"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07282795","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-03-31","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":670},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT06507553","phase":"PHASE1","title":"Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-08-12","conditions":"Influenza, Healthy Volunteers","enrollment":400},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03179761","phase":"PHASE2","title":"High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-10-09","conditions":"Hematopoietic Cell Transplantation","enrollment":124},{"nctId":"NCT02860039","phase":"PHASE2","title":"High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2016-09","conditions":"Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza","enrollment":170},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT03722589","phase":"PHASE4","title":"Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-09-12","conditions":"Influenza","enrollment":944},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT03293498","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-09-18","conditions":"Influenza","enrollment":330},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT01808456","phase":"PHASE4","title":"Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2013-10","conditions":"Influenza, Human, Transplantation Infection","enrollment":62},{"nctId":"NCT03282240","phase":"PHASE3","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-08","conditions":"Influenza","enrollment":2670},{"nctId":"NCT02787044","phase":"PHASE4","title":"INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-08-01","conditions":"Heart Failure, Myocardial Infarction","enrollment":5388},{"nctId":"NCT03068949","phase":"PHASE4","title":"Comparison of Three Licensed Influenza Vaccines","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-10-28","conditions":"Influenza","enrollment":413},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT01561989","phase":"NA","title":"Cholecalciferol and Flu Vaccine in Treating Healthy Participants","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-10","conditions":"Healthy, no Evidence of Disease","enrollment":11},{"nctId":"NCT02831751","phase":"PHASE2","title":"Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-04","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":1001},{"nctId":"NCT01216332","phase":"PHASE1","title":"Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-10","conditions":"Pediatric Patients With Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT00170482","phase":"","title":"Elderly Influenza Vaccine Immunogenicity Substudy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-04-25","conditions":"Influenza","enrollment":60},{"nctId":"NCT02263040","phase":"PHASE1, PHASE2","title":"A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-10","conditions":"Influenza","enrollment":170},{"nctId":"NCT01945268","phase":"PHASE4","title":"Influenza Vaccine To Prevent Adverse Vascular Events:Pilot","status":"COMPLETED","sponsor":"McMaster University","startDate":"2015-04","conditions":"Heart Failure","enrollment":107},{"nctId":"NCT02762851","phase":"PHASE4","title":"Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2016-06","conditions":"Heart Failure, Influenza","enrollment":5000},{"nctId":"NCT01924169","phase":"PHASE2","title":"Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-24","conditions":"Hematologic Disorder","enrollment":3},{"nctId":"NCT01815268","phase":"PHASE4","title":"High-Dose Influenza Vaccine in Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2013-02","conditions":"Influenza","enrollment":823},{"nctId":"NCT02035696","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-12","conditions":"Influenza","enrollment":671},{"nctId":"NCT01941758","phase":"PHASE1","title":"High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-11","conditions":"Central Nervous System Neoplasm","enrollment":28},{"nctId":"NCT01720277","phase":"PHASE4","title":"High Dose Influenza Vaccine in Nursing Home - Pilot Study","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2012-09","conditions":"Influenza","enrollment":2957},{"nctId":"NCT02553343","phase":"PHASE2","title":"A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":792},{"nctId":"NCT01685372","phase":"PHASE2","title":"Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-09","conditions":"Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV)","enrollment":16},{"nctId":"NCT03022396","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":82},{"nctId":"NCT03022422","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-09","conditions":"Influenza","enrollment":63},{"nctId":"NCT01827462","phase":"PHASE4","title":"Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-10","conditions":"Influenza","enrollment":136},{"nctId":"NCT01205581","phase":"PHASE2","title":"Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09","conditions":"HIV, Cancer","enrollment":85},{"nctId":"NCT01525004","phase":"PHASE1","title":"Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2011-09","conditions":"Pediatric Solid Organ Transplant Patients","enrollment":38},{"nctId":"NCT01666782","phase":"PHASE2","title":"Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy","status":"COMPLETED","sponsor":"Saad Jamshed MD","startDate":"2012-08","conditions":"Cancer, Influenza Viral Infections","enrollment":105},{"nctId":"NCT00551031","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Myxovirus Infection","enrollment":2098},{"nctId":"NCT01258595","phase":"PHASE2","title":"A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT00848848","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT00766285","phase":"PHASE2","title":"High Dose Influenza in Immunosuppressed Subjects","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza","enrollment":""},{"nctId":"NCT01427309","phase":"PHASE4","title":"A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09","conditions":"Influenza","enrollment":31989},{"nctId":"NCT01436370","phase":"PHASE2","title":"TIV and High Dose TIV in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-10","conditions":"Influenza","enrollment":102},{"nctId":"NCT00115531","phase":"PHASE2","title":"Eldery High Dose TIV 2005","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-04","conditions":"Influenza","enrollment":414},{"nctId":"NCT01691339","phase":"PHASE4","title":"Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-09","conditions":"Influenza","enrollment":200},{"nctId":"NCT01014806","phase":"PHASE2","title":"Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2009-11","conditions":"Influenza","enrollment":467},{"nctId":"NCT00903552","phase":"PHASE2","title":"Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)","status":"COMPLETED","sponsor":"Novavax","startDate":"2009-05","conditions":"Seasonal Influenza","enrollment":221},{"nctId":"NCT01561768","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-03","conditions":"Influenza","enrollment":500},{"nctId":"NCT01430819","phase":"PHASE4","title":"Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09","conditions":"Influenza","enrollment":300},{"nctId":"NCT01215734","phase":"PHASE1","title":"Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2010-10","conditions":"Adult Stem Cell Hematopoetic Transplant","enrollment":44},{"nctId":"NCT00845429","phase":"PHASE2","title":"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Orthomyxoviruses, Myxovirus Infection","enrollment":729},{"nctId":"NCT01031719","phase":"PHASE3","title":"Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-08","conditions":"H1N1 Influenza Virus, Invasive Solid Tumors","enrollment":59},{"nctId":"NCT00976027","phase":"PHASE3","title":"Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-09","conditions":"Influenza","enrollment":9172},{"nctId":"NCT01304563","phase":"NA","title":"2010/2011 Trivalent Influenza Vaccination","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2010-11","conditions":"Influenza","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High Dose Trivalent Influenza Vaccine","genericName":"High Dose Trivalent Influenza Vaccine","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"A high-dose formulation of trivalent influenza vaccine that stimulates a stronger immune response by delivering increased antigen quantities to enhance antibody production and cellular immunity against three influenza virus strains. Used for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in immunocompromised populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}